Structure Therapeutics, Inc. Sponsored ADR GPCR 深 滬
等待開盤 01-28 09:30:00 美东时间
89.51
-0.060
-0.07%
華盛通- 最 高91.21
- 今 開88.89
- 成交量 58.44万股
- 最 低 88.02
- 昨 收 89.57
- 總市值 51.56亿
- 52周最高 94.90
- 市盈率 靜 --
- 換手率 1.01%
- 52周最低 13.22
- 委 比 90.48%
- 總股本 5759.79万
- 歷史最高 94.90
- 量 比 0.45
- 振 幅 3.56%
- 歷史最低 13.22
- 每 手 1
- 風險率 17.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
Guggenheim Maintains Buy on Structure Therapeutics, Raises Price Target to $140
Guggenheim analyst Seamus Fernandez maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and raises the price target from $90 to $140.
01-20 22:15
美股周涨跌榜 | 算力基建再提速！Galaxy Digital 涨超37%，获批电力容量翻番；创新药企IBRX大涨近137%
算力基建再提速！Galaxy Digital 周涨超37%，获批电力容量翻番；创新药企IBRX周涨近137%，在研创新药获批上市>>
01-17 10:31
Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments
Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its experimental pill to market.
01-16 00:07
Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index falling around 250 points on T...
01-14 01:28
The Year-End 2025 Biotech Rally And What It Means For 2026
Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a ...
2025-12-31 23:54
美股牛股 | 石油天然气开发公司SOC涨超36%，管道系统重启计划获批通过；NUAI涨超11%
石油天然气开发公司SOC涨超36%，管道系统重启计划获批通过；NUAI涨超11%，完成收购关键大型数据中心项目；HYMC涨超10%，发现优质银矿>>
2025-12-24 14:46
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
Structure Therapeutics Initiates First-In-Human Phase 1 Clinical Study Of ACCG-2671, Lead Oral Small Molecule Amylin Receptor Agonist For Obesity Treatment
Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that it has
2025-12-17 21:38
